03 October 2024
The Botton-Champalimaud Pancreatic Cancer Centre, a cutting-edge facility dedicated to the treatment and research of pancreatic cancer, officially commenced all its surgical and inpatient activities this Monday, September 30, 2024. This marks a significant milestone in its phased opening, following the launch of external consultations during the summer.
With fully functional inpatient and recovery units, as well as operating rooms, the Centre is now prepared to significantly expand the Champalimaud Foundation's capacity to treat pancreatic cancer patients. With a dedicated team of specialists in the treatment and research of this type of cancer, the Centre's mission is to deliver the highest standard of clinical care. Driven by the latest medical and technological advancements, and adopting a multidisciplinary, patient-centred approach, the Centre also strives to provide solutions designed to meet the privacy and comfort needs of patients and their families.
A key element of the newly launched activity is the integration of the Botton-Champalimaud Pancreatic Cancer Centre within the broader Champalimaud Foundation. Leveraging the recognised and extensive expertise of the Champalimaud Clinical Centre teams, who have been providing top-tier healthcare over the past 13 years, the Botton-Champalimaud Pancreatic Cancer Centre benefits from this consolidated experience across its professional teams.
This latest development, with the opening of the Centre's main services, marks a significant moment in the global fight against pancreatic cancer. It reinforces the Centre's mission to offer increasingly specialised patient care, always research-driven and combined with innovative treatment strategies.
